Invimestrocel is a Cell Therapy owned by Athersys, and is involved in 9 clinical trials, of which 7 were completed, and 2 are ongoing.

Multistem (PF05285401) consists of a special class of human stem cells that have the ability to express a range of therapeutically relevant proteins and other factors, as well as form multiple cell types. Factors expressed by multistem have the potential to deliver a therapeutic benefit in several ways, such as the reduction of inflammation, protection of damaged or injured tissue, and the formation of new blood vessels in regions of ischemic injury. These cells exhibit a drug-like profile in that they act primarily through the production of factors that regulate the immune system, protect damaged or injured cells, promote tissue repair and healing and most or all of the cells are cleared from the body over time. Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and adult tissue (adult stem cells).

The revenue for Invimestrocel is expected to reach a total of $1.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Invimestrocel NPV Report.

Invimestrocel was originated by University of Minnesota and is currently owned by Athersys.

Invimestrocel Overview

Invimestrocel (PF05285401) is under development for the treatment of congestive heart failure, critical limb ischemia, graft versus host disease, peripheral arterial disease (PAD)/pulmonary vascular disease (PVD), multiple sclerosis, traumatic brain injury, spinal cord injury, solid organ transplantation, acute ischemic stroke, hemorrhagic stroke, cerebral infarction, for use in hematopoietic stem cell transplantation and pulmonary disorders such as pneumonia-induced acute respiratory distress syndrome (ARDS) and ARDS caused by coronavirus disease 2019 (COVID-19). The drug candidate is administered as an intravenous infusion. MultiStem is a biologic therapy that consists of undifferentiated human stem cells obtained from adult bone marrow or other non-embryonic tissue sources. It is a stem cell platform based on the multipotent adult progenitor cell (MAPC) technology.

It was also under development for acute leukemia, chronic myelocytic leukemia (CML), myelodysplastic syndrome (myelodysplasia), ulcerative colitis, type 1 diabetes, graft versus host disease (GVHD), acute myocardial infarction, Hurler’s syndrome and Parkinson's disease.

Athersys Overview

Athersys is a biotechnology company that discovers and develops novel and proprietary therapies in the field of regenerative medicine. It is investigating its lead platform, MultiStem, a patented stem cell product for treating chronic conditions such as cardiovascular diseases, inflammatory and immune disorders, neurological, and pulmonary disorders. The company’s MultiStem program includes product candidates at various levels of clinical trials for treating acute myocardial infarction, bone marrow/hematopoietic stem cell transplantation, ischemic stroke and autoimmune disease. The company’s pipeline consists of therapeutic product development programs in multiple disease areas, through the application of proprietary technologies. Athersys is headquartered in Cleveland, Ohio, the US.

The company reported revenues of (US Dollars) US$5.5 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$1.4 million in FY2020. The operating loss of the company was US$87.1 million in FY2021, compared to an operating loss of US$78.3 million in FY2020. The net loss of the company was US$87 million in FY2021, compared to a net loss of US$78.8 million in FY2020. The company reported revenues of US$0.1 million for the third quarter ended September 2022, a decrease of 97.2% over the previous quarter.

Quick View – Invimestrocel

Report Segments
  • Innovator
Drug Name
  • Invimestrocel
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Cardiovascular
  • Central Nervous System
  • Gastrointestinal
  • Genetic Disorders
  • Immunology
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Other Diseases
  • Respiratory
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.